* enVVeno Medical Corp NVNO.OQ reported a quarterly
adjusted
loss of 31 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -58 cents. The lone analyst forecast for the
quarter was for a loss of 36 cents per share.
* Reported revenue was zero; analysts expected zero.
* enVVeno Medical Corp's reported EPS for the quarter was a
loss
of 31 cents.
* The company reported a quarterly loss of $4.96 million.
* enVVeno Medical Corp shares had fallen by 1.7% this
quarter and
gained 0.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for enVVeno Medical
Corp is $20.40
This summary was machine generated from LSEG data August 5 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.36 -0.31 Beat
Mar. 31 2024 -0.40 -0.31 Beat
Dec. 31 2023 -0.46 -0.36 Beat
Sep. 30 2023 -0.48 -0.45 Beat